| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/14/2023 | 329.18% | HC Wainwright & Co. | → $10 | Reiterates | Buy → Buy |
| 05/22/2023 | 329.18% | HC Wainwright & Co. | → $10 | Reiterates | Buy → Buy |
| 11/16/2022 | 329.18% | BTIG | $21 → $10 | Maintains | Buy |
| 11/15/2022 | 329.18% | HC Wainwright & Co. | $12 → $10 | Maintains | Buy |
| 08/15/2022 | 415.02% | HC Wainwright & Co. | $3 → $12 | Maintains | Buy |
| 06/03/2022 | 801.29% | BTIG | $4 → $21 | Maintains | Buy |
| 05/16/2022 | 28.76% | HC Wainwright & Co. | $4 → $3 | Maintains | Buy |
| 05/18/2021 | 71.67% | BTIG | → $4 | Initiates Coverage On | → Buy |
| 05/14/2021 | 71.67% | HC Wainwright & Co. | $3.5 → $4 | Maintains | Buy |
| 04/26/2021 | 63.09% | Mizuho | → $3.8 | Initiates Coverage On | → Buy |
| 10/23/2020 | 114.59% | Oppenheimer | → $5 | Initiates Coverage On | → Outperform |
| 03/24/2020 | 50.21% | HC Wainwright & Co. | $7 → $3.5 | Maintains | Buy |
What is the target price for CASI Pharmaceuticals (CASI)?
The latest price target for CASI Pharmaceuticals (NASDAQ: CASI) was reported by HC Wainwright & Co. on August 14, 2023. The analyst firm set a price target for $10.00 expecting CASI to rise to within 12 months (a possible 329.18% upside). 5 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for CASI Pharmaceuticals (CASI)?
The latest analyst rating for CASI Pharmaceuticals (NASDAQ: CASI) was provided by HC Wainwright & Co., and CASI Pharmaceuticals reiterated their buy rating.
When is the next analyst rating going to be posted or updated for CASI Pharmaceuticals (CASI)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of CASI Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for CASI Pharmaceuticals was filed on August 14, 2023 so you should expect the next rating to be made available sometime around August 14, 2024.
Is the Analyst Rating CASI Pharmaceuticals (CASI) correct?
While ratings are subjective and will change, the latest CASI Pharmaceuticals (CASI) rating was a reiterated with a price target of $0.00 to $10.00. The current price CASI Pharmaceuticals (CASI) is trading at is $2.33, which is within the analyst's predicted range.